Cancer Prevention Pharmaceuticals

Category: Drugs & Pharmaceuticals

Cancer Prevention Pharmaceuticals is using technology developed by researcher Eugene Gerner at the University of Arizona Cancer Center, using a novel strategy of drug therapy for the prevention of colorectal cancer recurrence.

Phase III trials have already shown a 95% efficacy for this modality.

The mission of CPP is to conduct Food and Drug Administration (FDA) registration trials for chemoprevention of specific cancers. Our initial focus is the prevention of colorectal cancer (CRC) in high risk groups, including individuals with prior CRC or advanced colorectal adenomas (CRA), or those with genetic risk factors such as familial adenomatous polyposis (FAP).